NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹25 Cr | ₹61 Cr | ₹101 Cr | ₹135 Cr | ₹143 Cr |
What is the latest Total Non-Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹25 Cr |
| Mar2024 | ₹61 Cr |
| Mar2023 | ₹101 Cr |
| Mar2022 | ₹135 Cr |
| Mar2021 | ₹143 Cr |
How is Total Non-Current Liabilities of NATCO PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹25 Cr | -59.18 | |
| Mar2024 | ₹61 Cr | -39.30 | |
| Mar2023 | ₹101 Cr | -25.61 | |
| Mar2022 | ₹135 Cr | -5.46 | |
| Mar2021 | ₹143 Cr | - | |
Compare Total Non-Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹17,331.5 Cr | 3.6% | 11.4% | 5.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,982.0 Cr | 0.9% | 5.6% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,361.0 Cr | 1.2% | 3.7% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,737.0 Cr | 4.4% | 10.3% | 42.1% | Stock Analytics | |
| CIPLA | ₹115,655.0 Cr | -1.7% | 3.1% | -4.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,573.0 Cr | 0.2% | 5.7% | 6% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 3.6% |
11.4% |
5.5% |
| SENSEX | -0.5% |
3% |
-8.5% |
You may also like the below Video Courses